Arbutus Biopharma

NSQ:ABUS · CA03879J1003

BiotechnologySmall

360° View

Value30

Price/Sales15

Price/Earnings88

Price/Book43

Dividend Yield—

Growth30

Revenue Growth11

Profit Growth91

Capital Growth8

TSR 52w39

Safety100

Leverage77

Liquidity100

Refinancing99

Combined47

Sentiment51

Analyst Opinions35

Pro Holdings43

Opinion Changes50

Market Pulse73

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2005

Employees44

Websitearbutusbio.com

ISINCA03879J1003

Last UpdateApr 2, 2026

Index & Theme

HepatologyInfectious DiseasesVaccinesBiopharmaBiotechnologyGeneticsMedicalPharmaceutical

Description

Arbutus Biopharma Corporation (Arbutus) is a clinical-stage biopharmaceutical company focused on infectious disease. The company is developing imdusiran (AB-729), its proprietary, GalNAc-conjugated, subcutaneously-delivered ribonucleic acid interfer…

Analysis

Arbutus Biopharma's 360° View rank of 43 places it below its peer average — better than 43% of its true peers.

It's growing slowly (30) and on the expensive side (30). On safety it is very well financed (100), and the market shows favorable sentiment (51). Taken together, its Combined rank of 47 reads as below its peer average.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Arbutus Biopharma with its peers

MacroGenics

NSQ:MGNX

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Immuneering

NMQ:IMRX

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Vir Biotechnology

NSQ:VIR

CountryUSA

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Inhibikase Therapeutics

NAQ:IKT

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

ALX Oncology Holdings

NSQ:ALXO

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Erasca

NSQ:ERAS

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →